330.33
-0.90 (-0.27%)
| Previous Close | 331.23 |
| Open | 331.76 |
| Volume | 92,385 |
| Avg. Volume (3M) | 404,483 |
| Market Cap | 7,293,752,320 |
| Price / Sales | 37.78 |
| Price / Book | 9.36 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2025 - 9 May 2025 |
| Profit Margin | -258.64% |
| Operating Margin (TTM) | -64.84% |
| Diluted EPS (TTM) | -21.92 |
| Total Debt/Equity (MRQ) | 15.85% |
| Current Ratio (MRQ) | 6.10 |
| Operating Cash Flow (TTM) | -455.57 M |
| Levered Free Cash Flow (TTM) | -296.99 M |
| Return on Assets (TTM) | -36.98% |
| Return on Equity (TTM) | -80.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 8.79% |
| % Held by Institutions | 105.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Paulson & Co. Inc. | 31 Dec 2024 | 2,042,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 469.00 (Citigroup, 41.98%) | Buy |
| Median | 450.50 (36.38%) | |
| Low | 405.00 (HC Wainwright & Co., 22.61%) | Buy |
| Average | 442.50 (33.96%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 328.63 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 02 May 2025 | 460.00 (39.25%) | Buy | 326.79 |
| Canaccord Genuity | 02 May 2025 | 420.00 (27.15%) | Buy | 326.79 |
| UBS | 02 May 2025 | 458.00 (38.65%) | Buy | 326.79 |
| JMP Securities | 24 Apr 2025 | 443.00 (34.11%) | Buy | 319.93 |
| Citigroup | 27 Feb 2025 | 469.00 (41.98%) | Buy | 335.74 |
| HC Wainwright & Co. | 27 Feb 2025 | 405.00 (22.60%) | Buy | 335.74 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |